Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance increases since the launch of its Wegovy weight-loss drug, as US ...

Novo Nordisk A/S trimmed its forecasts as sales of the drugmaker’s blockbuster obesity and diabetes medicines struggle with ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on Wednesday, ending a ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

The 62-year-old company, which has moved into the prescription drug weight loss business, hopes to emerge from bankruptcy ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Gov. Glenn Youngkin saved about $7 million in state funds and $40 million in federal funds by vetoing a lower body-mass index ...